Sabine Brookman-May, Professor of Urology at Universität München, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post by Tyler Seibert, Assistant Professor in the Division of Radiation Oncology and a member of the RMAS Center for Precision Radiation Medicine (CPRM) on X, adding:
“As the Clinical Lead at JandJ at that time writing the PROTEUS protocol and defining the specific PET-based MFS endpoint, I am curious to see the final official results at ASCO as well.
A few considerations:
- As PSMA PET imaging was not integrated in the study from the beginning, this endpoint will only be available for a subset of patients
- PET based MFS is defined in a specific way for PROTEUS as aligned with the FDA – not every positive PET scan counted
- Subsequent therapy is important to consider which is often initiated prior to reaching conventional MFS
- QoL is one key aspect to consider. Concerning erectile function, I’d expect that in cases with nerve sparing surgery and perioperative function (limited subset in a HR setting) recovery will be good
- We will need to consider PROTEUS results together with results from other trials in this early setting including the BCR setting
- Finally, it will be most important to develop treatment strategies for patients resulting in as much as possible Freedom From Clinical Deterioration (FFCD) with as limited as possible subsequent treatment needed – new endpoints are needed!”
Quoting Tyler Seibert‘s post:
“Important considerations for Proteus as ASCO26 approaches.
MFS is a challenging endpoint when we have PSMA PET available (whether it counts as an event or not).”
Other Articles Featuring Sabine Brookman-May and Tyler Seibert on OncoDaily.